Letters to Healthcare Providers
|
| |
| EMA concludes review of weight management medicine Mysimba (naltrexone ／ bupropion) - Benefits continue to outweigh risks, with new risk minimisation measures and more information to be provided about long-term effect on the heart (Letter to Healthcare Professionals) |
| |
| |
| |
|
|
